TGF-β2 reduces demyelination, virus antigen expression, and macrophage recruitment in a viral model of multiple sclerosis

Kristen M. Drescher, Paul D. Murray, Xiaoqi Lin, Joseph A. Carlino, Moses Rodriguez

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

TGF-β2 is a potent immunoregulatory mediator that influences B cell, T cell, and macrophage function. To test whether this cytokine alters pathology in a model of virus-induced demyelinating disease, we treated SJL/J mice with TGF-β2 either before or after infection with Theiler's murine encephalomyelitis virus. Treatment continued three times weekly through day 35 postinfection. TGF-β2 administration resulted in significantly smaller lesions and fewer virus Ag-positive cells in the spinal cords of infected SJL/J mice. Mice treated with TGF-β2 had similar levels of virus-specific IgG as infected, control-treated mice. TGF-β2 administration significantly increased the level of non-virus-specific activated CTLs, but had no effect on virus-specific CTLs. TUNEL revealed a decrease in the number of apoptotic nuclei in the spinal cord white matter of mice treated in vivo with TGF-β2. Immunostaining with an Ab to F4/80 revealed that TGF-β2-treated mice had significantly fewer F4/80-positive cells in the white matter of the spinal cord as compared with infected control-treated mice. These data suggest that TGF-β2 may control virus-induced demyelination via an immunomodulatory mechanism that reduces macrophage infiltration.

Original languageEnglish
Pages (from-to)3207-3213
Number of pages7
JournalJournal of Immunology
Volume164
Issue number6
StatePublished - Mar 15 2000

Fingerprint

Demyelinating Diseases
Multiple Sclerosis
Macrophages
Viruses
Antigens
Spinal Cord
Theilovirus
In Situ Nick-End Labeling
B-Lymphocytes
Immunoglobulin G
Pathology
Cytokines
T-Lymphocytes
Infection

All Science Journal Classification (ASJC) codes

  • Immunology

Cite this

TGF-β2 reduces demyelination, virus antigen expression, and macrophage recruitment in a viral model of multiple sclerosis. / Drescher, Kristen M.; Murray, Paul D.; Lin, Xiaoqi; Carlino, Joseph A.; Rodriguez, Moses.

In: Journal of Immunology, Vol. 164, No. 6, 15.03.2000, p. 3207-3213.

Research output: Contribution to journalArticle

Drescher, Kristen M. ; Murray, Paul D. ; Lin, Xiaoqi ; Carlino, Joseph A. ; Rodriguez, Moses. / TGF-β2 reduces demyelination, virus antigen expression, and macrophage recruitment in a viral model of multiple sclerosis. In: Journal of Immunology. 2000 ; Vol. 164, No. 6. pp. 3207-3213.
@article{d1e483f88a884dcea02c353608ad73ed,
title = "TGF-β2 reduces demyelination, virus antigen expression, and macrophage recruitment in a viral model of multiple sclerosis",
abstract = "TGF-β2 is a potent immunoregulatory mediator that influences B cell, T cell, and macrophage function. To test whether this cytokine alters pathology in a model of virus-induced demyelinating disease, we treated SJL/J mice with TGF-β2 either before or after infection with Theiler's murine encephalomyelitis virus. Treatment continued three times weekly through day 35 postinfection. TGF-β2 administration resulted in significantly smaller lesions and fewer virus Ag-positive cells in the spinal cords of infected SJL/J mice. Mice treated with TGF-β2 had similar levels of virus-specific IgG as infected, control-treated mice. TGF-β2 administration significantly increased the level of non-virus-specific activated CTLs, but had no effect on virus-specific CTLs. TUNEL revealed a decrease in the number of apoptotic nuclei in the spinal cord white matter of mice treated in vivo with TGF-β2. Immunostaining with an Ab to F4/80 revealed that TGF-β2-treated mice had significantly fewer F4/80-positive cells in the white matter of the spinal cord as compared with infected control-treated mice. These data suggest that TGF-β2 may control virus-induced demyelination via an immunomodulatory mechanism that reduces macrophage infiltration.",
author = "Drescher, {Kristen M.} and Murray, {Paul D.} and Xiaoqi Lin and Carlino, {Joseph A.} and Moses Rodriguez",
year = "2000",
month = "3",
day = "15",
language = "English",
volume = "164",
pages = "3207--3213",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "6",

}

TY - JOUR

T1 - TGF-β2 reduces demyelination, virus antigen expression, and macrophage recruitment in a viral model of multiple sclerosis

AU - Drescher, Kristen M.

AU - Murray, Paul D.

AU - Lin, Xiaoqi

AU - Carlino, Joseph A.

AU - Rodriguez, Moses

PY - 2000/3/15

Y1 - 2000/3/15

N2 - TGF-β2 is a potent immunoregulatory mediator that influences B cell, T cell, and macrophage function. To test whether this cytokine alters pathology in a model of virus-induced demyelinating disease, we treated SJL/J mice with TGF-β2 either before or after infection with Theiler's murine encephalomyelitis virus. Treatment continued three times weekly through day 35 postinfection. TGF-β2 administration resulted in significantly smaller lesions and fewer virus Ag-positive cells in the spinal cords of infected SJL/J mice. Mice treated with TGF-β2 had similar levels of virus-specific IgG as infected, control-treated mice. TGF-β2 administration significantly increased the level of non-virus-specific activated CTLs, but had no effect on virus-specific CTLs. TUNEL revealed a decrease in the number of apoptotic nuclei in the spinal cord white matter of mice treated in vivo with TGF-β2. Immunostaining with an Ab to F4/80 revealed that TGF-β2-treated mice had significantly fewer F4/80-positive cells in the white matter of the spinal cord as compared with infected control-treated mice. These data suggest that TGF-β2 may control virus-induced demyelination via an immunomodulatory mechanism that reduces macrophage infiltration.

AB - TGF-β2 is a potent immunoregulatory mediator that influences B cell, T cell, and macrophage function. To test whether this cytokine alters pathology in a model of virus-induced demyelinating disease, we treated SJL/J mice with TGF-β2 either before or after infection with Theiler's murine encephalomyelitis virus. Treatment continued three times weekly through day 35 postinfection. TGF-β2 administration resulted in significantly smaller lesions and fewer virus Ag-positive cells in the spinal cords of infected SJL/J mice. Mice treated with TGF-β2 had similar levels of virus-specific IgG as infected, control-treated mice. TGF-β2 administration significantly increased the level of non-virus-specific activated CTLs, but had no effect on virus-specific CTLs. TUNEL revealed a decrease in the number of apoptotic nuclei in the spinal cord white matter of mice treated in vivo with TGF-β2. Immunostaining with an Ab to F4/80 revealed that TGF-β2-treated mice had significantly fewer F4/80-positive cells in the white matter of the spinal cord as compared with infected control-treated mice. These data suggest that TGF-β2 may control virus-induced demyelination via an immunomodulatory mechanism that reduces macrophage infiltration.

UR - http://www.scopus.com/inward/record.url?scp=0034653933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034653933&partnerID=8YFLogxK

M3 - Article

C2 - 10706712

AN - SCOPUS:0034653933

VL - 164

SP - 3207

EP - 3213

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 6

ER -